- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04522193
Dumping Syndrome and Esophageal Atresia (DUMTORING)
April 22, 2021 updated by: University Hospital, Lille
Physiopathology of Dumping Syndrome in Esophageal Atresia
Dumping syndrome (DS) is frequent in oesophageal atresia (29%).
In causing hypoglycaemia, it can be dangerous for neonates.
Mechanisms of DS are actually partialy understood.
This is also an affection difficult to diagnose, because it only occurs after meals and can be inconstantly present.
To date, their is only symptomatic treatment for DS.
This study aims to understand its pathological mechanisms so as to better treat it and avoid its consequences.
Oesophageal atresia patients enrolled in this study will benefit from a continuous glycemic monitoring, a continuous cardiac monitoring, and an a gastric emptying scintigraphy at the age of 3 months
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Madelaine AUMAR, MD
- Phone Number: 0320445962
- Email: madeleine.aumar@chru-lille.fr
Study Locations
-
-
-
Lille, France, 59037
- Hôpital Jeanne de Flandres
-
Principal Investigator:
- Madelaine AUMAR, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months to 3 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients operated at birth for Oesophageal atresia type C
- Aged from 2 to 3 months at inclusion
- Off prokinetic treatment (suspended for at least 72 hours) before monitoring
Exclusion Criteria:
- History of dumping syndrome of other cause (microgastria, fundoplication, dysautonomia..)
- History of any disease that can modify glycemic regulation (hyperinsulinism, neonatal diabete)
- Treatment that can modify gastric motility
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
All children born at the Lille University Hospital during the investigation period with esophageal atresia type III or IV
|
Continuous glycaemia monitoring,
Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
continuous cardiac monitoring
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abnormal glycaemia associated with vagal hypertonia
Time Frame: At least once during the 48 hours monitoring
|
Composite criteria: association between abnormal glycaemia (high or low) and variations of cardiac frequency
|
At least once during the 48 hours monitoring
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abnormal glycaemia associated with abnormal gastric emptying
Time Frame: At least once during the 48 hours monitoring
|
Composite criteria: association between abnormal glycaemia (high or low) and abnormal gastric emptying study
|
At least once during the 48 hours monitoring
|
Persistance of dumping syndrome
Time Frame: At the age of 6 months
|
measured by a gastric emptying scintigraphy
|
At the age of 6 months
|
Tolerance of glucose monitoring
Time Frame: At least once during the 48 hours monitoring
|
Occurrence of side effects or technical issues during monitoring
|
At least once during the 48 hours monitoring
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Madelaine AUMAR, MD, University Hospital, Lille
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2021
Primary Completion (Anticipated)
November 1, 2023
Study Completion (Anticipated)
November 1, 2023
Study Registration Dates
First Submitted
August 18, 2020
First Submitted That Met QC Criteria
August 18, 2020
First Posted (Actual)
August 21, 2020
Study Record Updates
Last Update Posted (Actual)
April 23, 2021
Last Update Submitted That Met QC Criteria
April 22, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019_51
- 2020-A01938-31 (Other Identifier: ID-RCB number,ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dumping Syndrome
-
Universitaire Ziekenhuizen KU LeuvenCompletedPostoperative Dumping SyndromeBelgium
-
University Hospital, Basel, SwitzerlandCompletedBariatric Surgery | Postprandial Hypoglycemia | Late Dumping SyndromeSwitzerland
-
Radboud University Medical CenterUnknown
-
Technological Educational Institute of ThessalyRecruiting
-
Universitaire Ziekenhuizen KU LeuvenIpsenCompleted
-
Novartis PharmaceuticalsCompletedDumping SyndromeBelgium, Netherlands, Germany, France, United States
-
Larissa University HospitalRecruitingDumping Syndrome | Gastric SurgeryGreece
-
University Hospital, LilleCompleted
-
Cambridge University Hospitals NHS Foundation TrustCompleted
-
University Hospital Inselspital, BerneCompletedDumping Syndrome | Hypoglycemia, ReactiveSwitzerland
Clinical Trials on Glycemic Holter
-
Centre d'Etudes et de Recherche pour l'Intensification...CompletedDiabetes Mellitus, Type I | Adjustment of Basal Insulin Flow Rate During Physical Activity | Adjustment of Prandial Insulin in Case of Physical ActivityFrance
-
Universidad Autonoma de Baja CaliforniaTerminated
-
Federico II UniversityUnknown
-
Indiana UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingPregnancy, High Risk | Overweight and Obesity | Gestational DiabetesUnited States
-
Vrije Universiteit BrusselKU LeuvenCompleted
-
The University of Texas Health Science Center,...National Institutes of Health (NIH)Terminated
-
Unilever R&DMaastricht UniversityCompletedGlucose Metabolism DisordersNetherlands
-
University of California, DavisCompleted
-
Centre Hospitalier Universitaire DijonCompletedSeptic Shock | Atrial FibrillationFrance
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedCluster HeadacheFrance